Latest Healthcare Technology News

Alcidion Group has expanded its contract with Leidos Australia, adding $12.3 million in value and increasing annual recurring revenue by $2.5 million through to 2028.

Memphasys Limited has successfully raised over $1.1 million through a pro-rata entitlement offer to accelerate the commercialisation of its innovative Felix™ sperm selection system, targeting key regulatory approvals and market expansion.

MedAdvisor Limited has appointed John Ciccio as its new CEO and Managing Director, marking a strategic leadership shift aimed at capitalising on recent technology advancements and US market growth.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.

ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.

Adherium Limited reports a strong quarter with a 55% increase in device shipments and groundbreaking clinical results from its iCARE study, alongside securing over $2.6 million in post-quarter funding.

HeraMED has bolstered its cash position with a $1.98 million capital raise and is on the cusp of finalizing two pivotal U.S. commercial agreements, signaling a major step forward for its digital maternity care platform.

Oakridge International reports robust Q1 2025 results with strong sales and technology advances, while managing a potential legal claim.

Micro-X Ltd has secured its largest-ever $3.3 million Rover Plus order from Malaysia’s Ministry of Health and is progressing critical Head CT imaging trials, supported by a $4.4 million government grant.

Enlitic, Inc. reported a strong quarter with record cash receipts and contract wins, yet withdrew its revenue guidance due to delayed project completions. The company remains confident in reaching operational cash flow break-even by the end of Q4 FY25.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.